Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND Study
2024-516643-64-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of apixaban in Cardiac valve disease (VHD) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Composite efficacy endpoint. Planned start May 2025; status: authorised.
02
Drugs
apixaban
03
Conditions
Cardiac valve disease (VHD)
Beyond the preview
Go deeper on 2024-516643-64-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516643-64-00.